Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion.
BACKGROUND
P-selectin has recently been shown to be essential for leukocyte rolling after the reperfusion of ischemic mesentery. However, the mediators responsible for neutrophil rolling in ischemic microvessels remain entirely unclear.


RESULTS
Intravital microscopy was used to examine leukocyte kinetics in a feline mesentery ischemia/reperfusion model. Sixty minutes of ischemia followed by reperfusion caused a profound increase in leukocyte rolling and adhesion. Pretreatment with the endogenous antithrombotic agent antithrombin III (ATIII) infused as a bolus (250 U/kg) reduced neutrophil rolling and adhesion to preischemic levels during reperfusion. No effect was seen with heat-inactive ATIII. Importantly, ATIII posttreatment also significantly reduced neutrophil rolling and adhesion during reperfusion, suggesting that ATIII can reverse the leukocyte recruitment response induced by ischemia/reperfusion. Vascular permeability was also reduced by 50% after ATIII administration. To determine whether ATIII could reverse thrombin-induced rolling directly, neutrophil rolling was performed on human endothelium in flow chambers. Indeed, thrombin-induced rolling, but not histamine-induced rolling, could be rapidly reversed with ATIII on endothelium, suggesting that ATIII affects thrombin rather than directly affecting neutrophils or the endothelium.


CONCLUSIONS
This study demonstrates for the first time that thrombin plays an important role in ischemia-induced leukocyte rolling and adhesion and that ATIII can be used therapeutically postreperfusion to attenuate the leukocyte recruitment response in inflammation without the nonspecific effects associated with anti-adhesion molecule therapy.
Ostrovsky
L
L
Department of Physiology and Biophysics, University of Calgary, Alberta, Canada.
Woodman
R C
RC
Payne
D
D
Teoh
D
D
Kubes
P
P
D000818:Animals; D000990:Antithrombin III / Q000494:pharmacology*; D001783:Blood Flow Velocity / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D002415:Cats; D002448:Cell Adhesion; D002478:Cells, Cultured; D002634:Chemotaxis, Leukocyte / Q000187:drug effects*; D004730:Endothelium, Vascular / Q000187:drug effects / Q000502:physiology*; D006632:Histamine / Q000494:pharmacology; D006801:Humans; D007511:Ischemia; D007962:Leukocytes / Q000187:drug effects / Q000502:physiology*; D017538:Mesenteric Artery, Superior / Q000187:drug effects / Q000502:physiology / Q000503:physiopathology*; D015427:Reperfusion Injury / Q000503:physiopathology*; D013917:Thrombin / Q000494:pharmacology; D014471:Umbilical Veins; D014699:Venules / Q000187:drug effects / Q000502:physiology
D006632:Histamine; D000990:Antithrombin III; D013917:Thrombin